Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
France Targets Shein, Temu With Fast-Fashion Fees 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Add as a preferred source on Google
REDWOOD CITY, Calif., March 13, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective March 12, 2018, the compensation committee of the company’s board of directors granted 2 new employees options to purchase an aggregate of 37,000 shares of the company’s common stock with a per share exercise price of $12.45, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
